Presentations

CoreValve for High Risk and Extreme Risk Patients; The US Pivotal Trials

solaci
solaci
239
0

7_eduardo_de-marchena
Eduardo de Marchena
2014-10-30

M.D., F.A.C.C., F.A.C.P., F.S.C.A.I.
Professor of Medicine & Surgery
Associate Dean for International Medicine
Director of Interventional Cardiology
University of Miami Miller School of Medicine

Previous article
Importancia de la Estratificación de Riesgo en SCA
Next article
Endovascular treatment of Mitral Paravalvular Leaks
solaci
solaci

More articles by this author

Stroke

solaci - 0
Rutger-Jan Nuis 2014-10-30MD, MSc, PhDDepartment of CardiologyThoraxcenter Rotterdam, Netherlands

Intervencionismo Coronario en Venas Centrales

solaci - 0
Jorge Villegas2014-10-30Cardiólogo IntervencionistaProfesor: F.U.C.S.Jefe de Hemodinmia Hospital Universitario Clínica San Rafael

TAVI-Induced Conduction Abnormalities

solaci - 0
Rutger-Jan Nuis 2014-10-30MD, MSc, PhDDepartment of CardiologyThoraxcenter Rotterdam, Netherlands

In Perspective: Impact of new TAVI Devices on TAVI Complications

solaci - 0
Eberhard Grube2014-10-30MD, FACC, FSCAIUniversity Hospital, Dept of Medicine II, Bonn, GermanyStanford University, Palo Alto, California, USA 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Presentations

Stroke

Rutger-Jan Nuis 2014-10-30MD, MSc, PhDDepartment of CardiologyThoraxcenter Rotterdam, Netherlands
solaci -
SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

Dr. Omar Tupayachi - 0
The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Dr. Andrés Rodríguez - 0
Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Dr. Juan Manuel Pérez - 0
Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...